
Found 6 results
Filters: Author is Fröhling, S [Clear All Filters]
Search Results
- Showing 1-6 of 6 Results
STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proceedings of the National Academy of Sciences of the United States of America, 2012/02/21, Volume 109, Issue 8, p.2860-5, (2012)
Read More / View Supplemental Materials
Abstract
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature, 2009/11/05, Volume 462, Issue 7269, p.108-12, (2009)
Read More / View Supplemental Materials
Abstract
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature, 2008/10/16, Volume 455, Issue 7215, p.975-8, (2008)
Read More / View Supplemental Materials
Abstract
Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood, 2008/09/01, Volume 112, Issue 5, p.1981-92, (2008)
Read More / View Supplemental Materials
Abstract
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer cell, 2007/12/01, Volume 12, Issue 6, p.501-13, (2007)
Read More / View Supplemental Materials
Abstract
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer cell, 2005/04/01, Volume 7, Issue 4, p.387-97, (2005)
Read More / View Supplemental Materials
Abstract
- Showing 1-6 of 6 Results




